Mechanistic study into the enhanced transdermal permeation of a model β-blocker, propranolol, by fatty acids: a melting point depression effect

Add time:09/07/2019    Source:sciencedirect.com

Transdermal permeation of propranolol through human skin in the presence of fatty acid (lauric, capric) penetration enhancers has been investigated. Thermal analysis showed that binary mixtures of propranolol with either fatty acid were not simple mechanical mixtures of the two components. Propranolol formed 1:1 molar addition compounds with both lauric and capric acids; the addition compound produced from propranolol and lauric acid (m.p. 79°C) also developed eutectic systems with both propranolol (m.p. 54°C) and lauric acid (m.p. 16°C). Similarly, the addition compound made from propranolol and capric acid (m.p. 97°C) formed eutectic systems with propranolol (m.p. 83°C) and capric acid (m.p. 15°C). Infrared analyses indicated that the addition compounds were fatty acid salts of the β-blocker. The nature of the species permeating through human epidermal membranes from binary mixtures of propranolol with the fatty acids was investigated using a novel attenuated total reflectance Fourier transform infrared method. There was no clear difference in permeation rates of the fatty acids compared with the β-blocker, suggesting that the permeating species was the intact addition compound. The influence of melting point depression of the β-blocker fatty acid systems on transdermal permeation was predicted from a mathematical model; predicted and experimentally determined data correlated well thus providing an alternative explanation as to the mode of action of these permeation enhancers.

We also recommend Trading Suppliers and Manufacturers of propranolol laurate (cas 138656-55-0). Pls Click Website Link as below: cas 138656-55-0 suppliers

Prev:Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire® core
Next:Research paperDemonstration of the importance of biphasic oleic acid delivery for enhancing the bioavailability of propranolol in healthy volunteers)